Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

What is it about?

This article describes the harmonized study protocols for 2 phase I clinical trials of a dendritic-cell based tolerance inducing therapy for multiple sclerosis. This therapy aims to precisely silence myelin-antigen-specific, putatively deleterious immune responses in MS. The primary outcome of the study is to assess safety and feasibility of this approach.

Featured Image